Lupin Launches Ganirelix Acetate Injection In U.S.

Pharma major Lupin Ltd on Thursday said it has launched Ganirelix Acetate injection indicated to women undergoing certain fertility treatments following approval from the U.S. health regulatory.

The U.S. Food and Drug Administration had approved Ganirelix Acetate injection, 250 mcg/0.5 mL, single-dose prefilled syringe and the same has been launched in the U.S. market, Lupin said in a regulatory filing.

It is a generic equivalent to the reference listed drug, Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.

The injection is indicated for the inhibition of premature Luteinizing Hormone surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix Acetate injection had estimated annual sales of $87 million in the U.S., Lupin said citing IQVIA MAT December 2023 data.